All news

Keros Therapeutics adds $5 million share buyback

Alpha Vantage · Yahoo! Finance Canada · · AI-summarised by FinFlash

Keros Therapeutics' board approved a new $5 million share repurchase program for its common stock, allowing management to buy shares in the open market with timing and amount dependent on market conditions. The authorization follows receipt of a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A. tied to the ELRiSE MF clinical trial.

Read original source

KROS company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.